Perhaps some disappointment around the EBITDA guidance, but the results commentary did suggest a stronger than expected NPAT in H2 2024 due to cost cutting. I guess the proof will be in the pudding. Initially I was pleased by the ex covid testing revenue growth (even accounting for acquisitions), but looking at the even stronger growth in costs, this put a bit of a dampener on it. As you said, no franking credit on dividend.
Ann: Half Yearly Report and Accounts, page-3
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$27.24 |
Change
0.560(2.10%) |
Mkt cap ! $13.08B | |||
| Open | High | Low | Value | Volume |
| $26.96 | $27.25 | $26.90 | $26.46M | 974.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 845 | $27.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $27.26 | 3124 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| SHL (ASX) Chart |